Legend Biotech (LEGN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Legend Biotech has announced the approval of its groundbreaking treatment for multiple myeloma, ciltacabtagene autoleucel (cilta-cel), by China’s National Medical Products Administration. This approval marks a significant advance in the treatment options available for adult patients in China who have not responded to traditional therapies. The decision by the NMPA was influenced by the promising results from Legend Biotech’s Phase 2 clinical study, offering new hope for those battling this challenging form of cancer.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.